Keros culls PAH asset, prompting layoffs for 70 workers
Keros Therapeutics is ending development of a phase 2 candidate designed to treat high blood pressure in the lungs, a move that has triggered layoffs for 45% of the biotech’s team.
Keros Therapeutics is ending development of a phase 2 candidate designed to treat high blood pressure in the lungs, a move that has triggered layoffs for 45% of the biotech’s team.
